Genoox, a Palo Alto, CA- based genomic analysis company, closed a $6m funding round.
The round was led by Triventures, joined by Inimiti Capital and Glilot Capital Partners. In conjunction with the funding, Dr. Peter Fitzgerald, Triventures’ co-founder and managing partner, and Genoox board member.
The company intends to use the funds to continue to expand operations and its business reach to more medical facilities in U.S.
Led by Amir Trabelsi, co-founder and CEO, Genoox provides a cloud-based genomic analysis platform that allows doctors, clinicians and researchers to analyze and act on genetic sequencing results by applying various clinical applications.
The company serves such customers as medical centers and research facilities, including the Center for Genetic Medicine Research at Children’s National Medical Center and the University of Michigan. In April, Genoox partnered with Bionano Genomics to create an integrated platform that enhances the detection of disease-causing structural variants in DNA.